Verition Fund Management
INO icon

Verition Fund Management’s Inovio Pharmaceuticals INO Stock Holding History

Verition Fund Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,504
Closed -$76.5K – 2867
2023
Q4 		$76.5K Sell
12,504
-12,500
-50% -$61.7K ﹤0.01% 2160
2023
Q3 		$117K Buy
25,004
+6,254
+33% +$34.5K ﹤0.01% 2095
2023
Q2 		$100K Buy
+18,750
New +$151K ﹤0.01% 1977
2021
Q2 		– Sell
-838
Closed -$93K – 2012
2021
Q1 		$93K Buy
+838
New +$110K ﹤0.01% 1443
2014
Q1 		– Sell
-866
Closed -$121K – 562
2013
Q4 		$121K Buy
+866
New +$86.7K 0.02% 435

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Verition Fund Management's INO Position: Q1 2024 in Review

Verition Fund Management sold out of Inovio Pharmaceuticals (INO) in Q1 2024, closing a stake of 12,504 shares — an estimated $76.5K sold.

Verition Fund Management first reported a position in INO in Q4 2013 and held it in 5 quarters. The position peaked at $121K in Q4 2013. 89 funds tracked by Wall St. Rank hold INO as of Q1 2024.

  • Verition Fund Management reported no remaining Inovio Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Verition Fund Management sold 12,504 Inovio Pharmaceuticals shares in Q1 2024, an estimated $76.5K.
  • Verition Fund Management first reported a position in Inovio Pharmaceuticals in Q4 2013 and held it in 5 quarters.
  • Verition Fund Management's Inovio Pharmaceuticals position peaked at $121K in Q4 2013.
  • 89 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2024.

Based on Verition Fund Management's 13F filing for Q1 2024, filed 14 May 2024.